Non Hodgkin's Lymphoma Clinical Trial
Official title:
Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | February 2015 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 65 Years |
Eligibility |
Inclusion Criteria: - Patients with a high-intermediate/high risk international prognostic index at a diagnosis or with salvage chemotherapy-sensitive relapse/refractory non Hodgkin's lymphoma - Patients with histologically confirmed diffuse large B cell lymphoma at diagnosis - Patients treated with rituximab based regimen previously - Patients who have not received therapy with high-dose chemotherapy and stem cell transplantation - Life expectation of at least 3 months - ECOG performance status = 2 (See Appendix II) - Adequate hepatic function (serum bilirubin less than 2.0 mg/dL, AST and ALT less than three times the upper normal limit) - Adequate renal function (serum creatinine less than 2.0 mg/dL). - Adequate cardiac function (ejection fraction = 45% on MUGA scan or echocardiogram). - Adequate bone marrow function (ANC = 1,000/mm3 and platelet count = 75,000/mm3). - All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right of trial abandon without any disadvantage Exclusion Criteria: - Patients with central nervous system involvement of lymphoma - Patients positive for human immunodeficiency virus - Pregnant or breast feeding woman - Young woman without pregnancy test prior to treatment or pregnancy test reveals positive. - Young woman without a reliable and proper contraceptive method - Man being not willing to contraception - Concurrent history of neoplasm other than NHL with life expectancy less than 3 months (except for curatively treated non-melanoma skin cancer or in-situ uterine cervix cancer). - History of clinically significant cardiac dysfunction (e.g. congestive heart failure, symptomatic coronary artery disease, medically uncontrolled arrhythmia) or myocardial infarction within 12 months - A psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible. - Significant infection or uncontrolled bleeding - Enrollment of other clinical trials within 4 weeks prior to treatment - Any preexisting medical condition of sufficient severity to prevent full compliance with the study - Patient being not willing to or unable to obey study protocol |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Inje University Busan Paik Hospital | Busan | |
Korea, Republic of | Asan Medical Center, University of Ulsan | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Yeonsei University Hospital | Seoul | |
Korea, Republic of | Ulsan University Hospital | Ulsan |
Lead Sponsor | Collaborator |
---|---|
Inje University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression-free survival | three year | No | |
Secondary | overall survival | three year | No | |
Secondary | Response rate according to the International Working Group criteria | after 2 month | No | |
Secondary | Adverse events | From start of conditioning to discharge | Yes | |
Secondary | •Pharmacogenetic study | Pharmacogenetic study for predictive or prognostic markers using blood samples | After 3 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06014073 -
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
Terminated |
NCT00909948 -
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
Recruiting |
NCT05370547 -
Chidamide Bridging for CAR-T Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
Completed |
NCT00477945 -
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
|
Phase 1 | |
Terminated |
NCT00038818 -
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT01789723 -
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
|
Phase 1 | |
Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
Terminated |
NCT00714259 -
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
|
Phase 2/Phase 3 | |
Completed |
NCT01018758 -
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
|
Phase 2 | |
Completed |
NCT00001830 -
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
|
Phase 1 | |
Completed |
NCT01527422 -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
|
Phase 1/Phase 2 | |
Completed |
NCT00834951 -
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04497688 -
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
Completed |
NCT00597714 -
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00001430 -
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
|
Phase 2 |